<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01838720</url>
  </required_header>
  <id_info>
    <org_study_id>RenJiH-20130406</org_study_id>
    <nct_id>NCT01838720</nct_id>
  </id_info>
  <brief_title>Zero Ischemia Laparoscopic Radio Frequency Ablation Assisted Enucleation of Renal Cell Carcinoma With T1a Stage</brief_title>
  <official_title>Zero Ischemia Laparoscopic Radio Frequency Ablation Assisted Enucleation of Renal Cell Carcinoma With T1a Stage : Clinical Outcomes of a Randomised Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>RenJi Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Natural Science Foundation of China</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>RenJi Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the feasibility and efﬁciency of zero ischemia laparoscopic radio frequency
      ablation assisted enucleation of T1a renal cell carcinoma in comparison with the conventional
      laparoscopic partial nephrectomy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Warm ischemic injury is one of the most important factors affecting renal function in partial
      nephrectomy (PN). Zero ischemia partial nephrectomy technique using renal arterial branch
      microdissection could protect renal function during surgery, but it requires longer operative
      time and more blood loss than conventional partial nephrectomy. The technique of zero
      ischemia laparoscopic radio frequency ablation assisted enucleation of renal cell carcinoma
      appears to be an alternative that eliminates warm ischemia, preserves the maximal parenchyma
      and is oncologically safe. Our study was designed to evaluate this technique in comparison
      with the conventional laparoscopic partial nephrectomy.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>April 2013</start_date>
  <completion_date type="Anticipated">October 2014</completion_date>
  <primary_completion_date type="Anticipated">October 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>the absolute change in glomerular ﬁltration rate (GFR) of the aﬀected kidney</measure>
    <time_frame>baseline and 12 months</time_frame>
    <description>12 months minus baseline</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>estimated GFR (eGFR)</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>changes in GFR of total kidneys by renal scintigraphyby</measure>
    <time_frame>baseline and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>blood loss</measure>
    <time_frame>during surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>surgical margin</measure>
    <time_frame>postoperative</time_frame>
    <description>pathologic confirm of surgical margin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>postoperative complications</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>progression-free survival</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>local recurrence</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the absolute change in glomerular ﬁltration rate (GFR) of the aﬀected kidney</measure>
    <time_frame>baseline and 6 months</time_frame>
    <description>6 months minus baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>estimated GFR (eGFR) of 6 month</measure>
    <time_frame>6 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>changes in GFR of total kidneys by renal scintigraphyby of 6 month</measure>
    <time_frame>6 month</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Renal Cell Carcinoma</condition>
  <condition>Zero Ischemia</condition>
  <arm_group>
    <arm_group_label>zero ischemia laparoscopic RFA assisted TE</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>RFA will be performed for 1 to 4 cycles for 4 to 12 minutes each depending on tumor size and depth. The tumor then will be laparoscopic enucleation without hilar clamping.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>conventional laparoscopic partial nephrectomy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Renal hilum will be accurately isolated and then the artery only will be clamped during surgery.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>zero ischemia laparoscopic RFA assisted TE</intervention_name>
    <arm_group_label>zero ischemia laparoscopic RFA assisted TE</arm_group_label>
    <other_name>zero ischemia laparoscopic radio frequency ablation assisted tumor enucleation</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>ischemia</intervention_name>
    <description>conventional laparoscopic partial nephrectomy</description>
    <arm_group_label>conventional laparoscopic partial nephrectomy</arm_group_label>
    <other_name>renal artery will be clamped during surgery.</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients with sporadic, unilateral, newly diagnosed T1a presumed renal cell carcinoma

          -  patients with normal contralateral renal function (diﬀerential renal function of &gt;40%
             as determined by radionuclide scintigraphy)

          -  patients agreeable to participate in this long-term follow-up study

        Exclusion Criteria:

          -  patients' aged &gt;80 years

          -  patients with other renal diseases

          -  patients not able to tolerate the laparoscopic procedure

          -  patients with previous renal surgery or history of any inﬂammatory conditions of the
             operative kidney

          -  patients with the renal tumor close to the calyces
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yiran Huang, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>RenJi Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yiran Huang, M.D.</last_name>
    <phone>86-13501835219</phone>
    <email>yrhuangrenji@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>RenJi Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200127</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yiran Huang, M.D.</last_name>
      <phone>86-13501835219</phone>
      <email>yrhuangrenji@163.com</email>
    </contact>
    <investigator>
      <last_name>Yiran Huang, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 14, 2013</study_first_submitted>
  <study_first_submitted_qc>April 20, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 24, 2013</study_first_posted>
  <last_update_submitted>August 12, 2014</last_update_submitted>
  <last_update_submitted_qc>August 12, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 13, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>RenJi Hospital</investigator_affiliation>
    <investigator_full_name>Yiran Huang</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>renal cell carcinoma</keyword>
  <keyword>ischemia</keyword>
  <keyword>radio frequency ablation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Ischemia</mesh_term>
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

